MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 890 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
KRAS G12C inhibitor 35
CAS:KRAS G12C inhibitor 35 targets KRAS G12C in cancer research (CN112920183A, compound 3).Fórmula:C31H27ClF2N6O3Cor e Forma:SolidPeso molecular:605.03KRAS G12C inhibitor 21
CAS:KRAS G12C inhibitor 21 is a KRAS G12C inhibitor.Fórmula:C34H30ClN3O4Cor e Forma:SolidPeso molecular:580.07TH-Z827
CAS:TH-Z827 is a mutant-selective inhibitor targeting KRAS(G12D) with an IC50 of 2.4 μM, demonstrating specificity by not binding to KRAS(WT) or KRAS(G12C).Fórmula:C30H38N6OPureza:98%Cor e Forma:SolidPeso molecular:498.66Uplarafenib
CAS:Uplarafenib (B-Raf IN 10), a potent BRAF inhibitor (IC50: 50-100 nM), exhibits antitumor effects on solid cancers.Fórmula:C22H21F3N4O4SPureza:99.98%Cor e Forma:SolidPeso molecular:494.49Ref: TM-T63333
1mg54,00€5mg119,00€10mg170,00€25mg359,00€50mg538,00€100mg928,00€1mL*10mM (DMSO)131,00€HPK1-IN-9
CAS:HPK1-IN-9: Potent MAP4K family kinase inhibitor targeting hematopoietic progenitor cells; potential in HPK1 diseases. (Patent WO2021213317A1)Fórmula:C30H33N7O2Cor e Forma:SolidPeso molecular:523.63DL-threo dihydrosphingosine
CAS:DL-threo dihydrosphingosine blocks ERK, inhibits smooth muscle proliferation, and works against growth factor/G-protein ERK activation.Fórmula:C18H39NO2Cor e Forma:SolidPeso molecular:301.51Inflachromene
CAS:Inflachromene (ICM) is an inhibitor of HMGB1 and HMGB expression with anti-inflammatory activity.Inflachromene is used in the study of epilepsy.Fórmula:C21H19N3O4Pureza:97.36% - 99.88%Cor e Forma:SolidPeso molecular:377.39Ref: TM-T24167
1mg109,00€5mg260,00€10mg416,00€25mg710,00€50mg973,00€100mg1.314,00€1mL*10mM (DMSO)286,00€KRAS G12C inhibitor 25
CAS:KRAS G12C inhibitor 25 blocks SOS1-mediated GDP/GTP swap in KRAS-G12C mutants; IC50: 0.48 nM (WO2021216770A1, comp. 3).Fórmula:C32H41N7O2Cor e Forma:SolidPeso molecular:555.71HPK1-IN-33
CAS:HPK1-IN-33 inhibits HPK1 with 1.7 nM potency, reduces IL-2 in Jurkat cells with 286 nM EC50, and is less effective in HPK1 KO cells.Fórmula:C18H16ClFN6Cor e Forma:SolidPeso molecular:370.81L 731734
CAS:L 731734 is a farnesyltransferase inhibitor.Fórmula:C19H38N4O3SCor e Forma:SolidPeso molecular:402.6KRAS G12C inhibitor 53
CAS:KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.Fórmula:C21H14ClF2N5O2Cor e Forma:SolidPeso molecular:441.82HPK1-IN-11
CAS:HPK1-IN-11 is a potent HPK1 inhibitor. HPK1-IN-11 has potential for the study of HPK1-related diseases.Fórmula:C27H25N5O2Cor e Forma:SolidPeso molecular:451.52KRAS G12C inhibitor 32
CAS:KRAS G12C Inhibitor 32, an eight-membered heterocyclic compound with nitrogen, acts as a potent inhibitor of KRAS G12C [1].Fórmula:C29H30Cl3FN6O3Pureza:98%Cor e Forma:SolidPeso molecular:635.94MS934
CAS:MS934, a novel VHL-recruiting MEK 1/2 degrader, exhibits potent anti-proliferative effects on HT-29 cell growth, achieving a GI50 of 0.023 μM.Fórmula:C52H69F3IN7O6SPureza:98%Cor e Forma:SolidPeso molecular:1104.11Glecirasib
CAS:Glecirasib (JAB-21822,KRAS G12C inhibitor 36) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits KRAS G12C-dependent signalingFórmula:C31H26ClF4N7O2Pureza:99.7% - >99.99%Cor e Forma:SolidPeso molecular:640.03KRAS G12C inhibitor 30
CAS:KRAS G12C inhibitor 30 is an inhibitor of KRAS G12C and can be used to study cancer.Fórmula:C25H22ClFN6O3Cor e Forma:SolidPeso molecular:508.93Pan-RAF kinase inhibitor 1
CAS:Potent Pan-RAF inhibitor 1 targets RAF/MAPK pathway, curbing RAS-mutated cancer cell growth. (Patent WO2021110141A1, compound 16B)Fórmula:C26H24F3N3O4Cor e Forma:SolidPeso molecular:499.48KRAS G12C inhibitor 51
CAS:KRAS G12C inhibitor 51 is a KRAS G12C inhibitor.Fórmula:C33H35FN6O3Cor e Forma:SolidPeso molecular:582.67HPK1-IN-10
CAS:HPK1-IN-10 inhibits HPK1, a MAP4K kinase from progenitor cells, with potential in treating HPK1 diseases, detailed in patent WO2021213317A1.Fórmula:C31H34N6O2Cor e Forma:SolidPeso molecular:522.64SOS1/KRAS-IN-1
CAS:SOS1/KRAS-IN-1 (Compound 2) serves as an inhibitor of SOS1/KRAS, with potential application in the study of diseases mediated by SOS1/KRAS [1].Fórmula:C24H26F3N5OPureza:98%Cor e Forma:SolidPeso molecular:457.49
